Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PAM | P19021 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6137577 | 1.00 | HMGCR (0.51) | HMGCRMAPTCYP3A4TSHRATM | |
| SCHEMBL6137456 | 1.00 | HMGCR (0.51) | HMGCRMAPTCYP3A4TSHRATM | |
| SCHEMBL6137307 | 1.00 | HMGCR (0.51) | HMGCRMAPTCYP3A4TSHRATM | |
| SCHEMBL6137449 | 1.00 | HMGCR (0.51) | HMGCRMAPTCYP3A4TSHRATM | |
| SCHEMBL6137305 | 1.00 | HMGCR (0.51) | HMGCRMAPTCYP3A4TSHRATM | |
| SCHEMBL6137532 | 0.94 | HMGCR (0.48) | HMGCRMAPTCYP3A4TSHRATM | |
| SCHEMBL6138656 | 0.94 | HMGCR (0.48) | HMGCRMAPTCYP3A4TSHRATM | |
| SCHEMBL6138650 | 0.94 | HMGCR (0.48) | HMGCRMAPTCYP3A4TSHRATM | |
| SCHEMBL6137527 | 0.94 | HMGCR (0.48) | HMGCRMAPTCYP3A4TSHRATM | |
| SCHEMBL8971601 | 0.90 | HMGCR (0.49) | HMGCRMAPTDGKAKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038259-A1 | Hydroxyeicosenoic acid anaglogs | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1425258-A4 | HYDROXYEICOSENOIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-02-16 | — | — | EP | disclosed |
| EP-1425258-A2 | HYDROXYEICOSENOIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003024390-A2 | HYDROXYEICOSENOIC ACID ANALOGS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038259-A1 | Hydroxyeicosenoic acid anaglogs | HCAR1, HRH4, HCAR3 | HMGCR 226/4885MAPT 4552/4885CYP3A4 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.